Therefore, c-Jun, along with partner AP-1 proteins that have also been shown to participate in the transcriptional network that tends to restore T-cell function after immune checkpoint blockade, are potential therapeutic targets in anti-tumor immunotherapy [49]. Here, JUND is linked to neoplasm.